The Danish pharmaceutical company Novo Nordisk, manufacturer of the famous drugs Ozempic and Wegovy approved by the Food and Drug Administration (FDA) for the control of type 2 diabetes and overweight It has managed to triple its market value in recent years.
Exceeding many of the estimates, the company has become one of the most important and with the most value in the stock market, even surpassing brands like Louis Vuitton; Since their first year of marketing, both drugs managed to generate millions of income for the pharmaceutical company.
Now for the closing of this Wednesday in its first trading session, The pharmaceutical company’s shares fell after its division in order to increase its liquidity. In just the first week of this month the value increased to about $426 billion.
It seems that the pharmaceutical company’s objective with these two drugs is not only to control one of the most important diseases such as diabetes, but also to generate a potential change in society.
These drugs have crept into all areas, especially in the artistic environment. Many celebrities have proven how effective they can be for weight control. and although many specialists have confirmed its effectiveness in diagnosed patients, not all have a positive perspective.
For UBS Group AG analyst Michael Leuchten, marketing and generating revenue from obesity is not shaping up to be profitable in the future compared to Novo’s current valuation. However, so far the increase in sales of both drugs Ozempic and Wegovy in the United States They have brought millions of dollars into Denmark’s economy.
In July, the Kaiser Family Foundation conducted a survey in which it determined that 50% of the population would be willing to take a medication like Wegovy to lose weight verifying its safety and effectiveness.
Therefore, Novo boom is expected to continue as it has already been doing, surpassing other pharmaceutical giants such as Roche or AstraZeneca (AZN) and its growth is expected to increase up to 37% more this year.
Keep reading:
Source: La Opinion
